ERBB2 and neoplasm: In detail, the most biologically aggressive subtypes, namely, triple-negative BC (TNBC) and HER2-positive (HER2+) BC, are characterized by high genomic instability and tumor mutational burden (TMB), both fueling the generation of neoantigens, ultimately fostering the antitumor immune activity.